导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 9.77% | 841/4773 |
| 近一周 | -2.83% | 4315/5465 |
| 近一月 | -3.10% | 2172/5421 |
| 近一季 | -3.58% | 1644/5231 |
| 近半年 | 6.12% | 763/4920 |
| 近一年 | 14.22% | 838/4394 |
| 近两年 | 73.56% | 952/2954 |
| 近三年 | 49.14% | 577/2253 |
| 成立以来 | 146.75% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-2.41% 2780/4961 |
22.67% 1116/5312 |
- - |
- - |
| 2025 | 31.33% 1248/4813 |
-0.72% 2374/3635 |
5.38% 602/4076 |
21.35% 1810/4524 |
3.43% 671/4813 |
| 2024 | 13.52% 1129/3463 |
1.66% 866/2808 |
-0.52% 778/3014 |
16.85% 1334/3129 |
-3.94% 2408/3463 |
| 2023 | -11.56% 1413/2656 |
1.50% 1561/2280 |
-4.13% 1067/2385 |
-0.97% 472/2515 |
-8.22% 2266/2655 |
| 2022 | -14.93% 401/2207 |
-13.18% 710/1919 |
9.00% 310/2016 |
-14.16% 1035/2113 |
4.71% 515/2208 |
| 2021 | 10.05% 444/1822 |
-1.59% 518/1255 |
8.07% 647/1330 |
-1.95% 550/1466 |
5.53% 286/1822 |
| 2020 | 85.41% 32/1250 |
-3.55% 307/1028 |
32.23% 32/1067 |
23.66% 30/1164 |
17.56% 121/1184 |
| 2019 | 47.11% 126/1092 |
21.96% 587/739 |
0.28% 174/788 |
10.87% 44/850 |
8.49% 310/918 |
| 2018 | - - |
- - |
-12.32% 387/631 |
-5.88% 385/660 |
-16.81% 648/682 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 富荣沪深300指数增强C VS. 长安沪深300非周期A(740101) |